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Abstract
The intricate relationship between economic conditions and natural fertility is known to influence both the timing and
number of children conceived. For infertile couples, the relationship between economics and fertility is more explicit because
of the necessity for many couples to pay for treatment to achieve childbirth. Consequently, affordability often dictates
whether or not someone is able to undergo treatment, as well as the types of treatments available. Economics can also be
used to describe treatment outcomes achieved through the use of fertility treatments. While gynaecologists and couples speak
of outcomes in terms of live births, economists are often inclined to view live births and their influence on society in
economic terms. In this review we consider two distinct elements of economics and assisted reproduction. Firstly, how
economics (i.e. affordability) can influence demand for, and access to, fertility treatments, and secondly, how methods for
valuing live births achieved using assisted reproductive technologies in economic terms can highlight the importance of these
children in the context of ageing populations. This review will attempt to illustrate that the economic benefits attributed to
children conceived through fertility treatments are much greater than health costs required for conception and should be
considered in future reimbursement decisions in this therapy area.
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Demand and affordability of ART
Over the past decade, the demand for assisted
reproductive technologies (ARTs) has increased
steadily with observable influences on national birth
rates (Andersen et al., 2008; Sobotka et al., 2008).
This increasing use of ARTs likely reflects many
factors including rising prevalence of infertility,
brought about by delays in time to first pregnancy,
increasing obesity and sexually transmitted disease as
well as increasing awareness and acceptance of
reproductive technology (Adashi et al., 2000; Kovacs
et al., 2003; Jensen et al., 2008). Prevalence
estimates from population-based surveys involving
more than 50,000 participants suggest that current
infertility during the preceding 12 months ranges
between 3.5 and 16.7% with a median of 9% (Boivin
et al., 2007). Despite high prevalence, the proportion
of infertile couples seeking advice and ultimately
pursuing treatment is likely to be 550% (Boivin
et al., 2007). The difference between prevalence
figures and utilisation reflects cultural, economic,
religious, physical and psychological barriers to
treatment.
Demand for, and consumption of, fertility treat-
ments likely requires that couples understand success
probabilities and associated risks such as multiple
pregnancy and ovarian hyperstimulation syndrome.
In markets where consumers pay for treatments,
successes and risks need to be balanced with
personal finances. Unfortunately, the extent to which
in-vitro fertilisation (IVF) couples are able to make
rational choices regarding multiple pregnancy risks
and associated costs does not always appear balanced
(Murray et al., 2004). In contrast, in markets where
the majority of costs are reimbursed, the affordability
is removed from the decision-making process and
couples can focus on outcomes. This explains why
more cycles are performed in countries with re-
imbursement (Sunde, 2007).
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Despite increasing demand for fertility treatments
and public support for public subsidy, healthcare
authorities often provide limited or no funding for
ART treatments (Adashi et al., 2000). Justification
for limiting reimbursement by funding authorities
derives from the opinion that infertility is a lifestyle
rather than a medical disorder, and consequently
considered a low priority (Redmayne & Klein, 1993).
Differing views of fund holders regarding the
prioritisation of infertility has resulted in sporadic
insurance coverage internationally with roughly 50%
of countries having no reimbursement through
national health services or private insurers (Jones
et al., 2007).
The relatively high cost for ART procedures
means that reimbursement of services is an impor-
tant element in ensuring delivery of care (Collins,
2002). Previous investigations have described the
relationship between ART reimbursement and an-
nual per capita treatment cycles (Jain et al., 2002;
Katz et al., 2002; Hammoud et al., 2009). Further-
more, an international comparison of treatment costs
in six countries has shown that lower costs paid by
consumers are associated with increased rates of
ART utilisation (Chambers et al., 2009). The price-
elasticity of demand associated with introducing a
co-payment for IVF and intracytoplasmic sperm
injection (ICSI) in Germany suggests that a 10%
increase in price likely reduces utilisation by 4.1%
and 3.4% for IVF and ICSI, respectively (Connolly
et al., 2009a). Unfortunately, studies have consis-
tently established that when treatment access is
dependent on user fees that these costs can be
preventative for many couples. Consequently cou-
ples with limited resources for treatment either go
without care or seek treatment abroad where user
fees are lower than in their home country (Pennings
et al., 2008).
The few studies available on costs of treatment and
access to care suggest that affordability is a powerful
determinant of whether couples will pursue treat-
ment; although non-financial barriers also do exist
(Hoorens et al., 2008). National survey data from the
United States (US) have shown that insurance
coverage and finances largely dictate whether women
will seek medical help to try and get pregnant
(Staniec & Webb, 2007). The availability and use
of IVF is also higher in US states with mandated
insurance coverage therefore minimising the finan-
cial barriers to care (Hammoud et al., 2009). A study
in Germany has shown that reductions in ART use
following the introduction of patient co-payments
was greatest in federal states with the lowest annual
gross domestic product (Griesinger et al., 2007).
Affordability and cost constraints can also influ-
ence clinical practice and treatment choices made by
consumers. Data from the US have shown that
insurance coverage can influence the number of
embryos transferred and consequently multiple birth
rates leading to increased healthcare costs (Reynolds
et al., 2003). In a survey of family growth in the US,
the impact of income and insurance status on access
to different levels of fertility service provision were
assessed. The investigators noted that seeking advice
(i.e. consultation) for infertility was the only fertility
service that was not influenced by either insurance
status or income level (Staniec & Webb, 2007). The
investigators also noted that insurance coverage
increased the likelihood that women would pursue
treatment with medications only or with surgery
compared with ‘no treatment’ observed with unin-
sured women. A trend showing that low-income
women were more likely to pursue the ‘no treatment’
option was also observed. Additionally, for low-
income women there was only an 11% chance that
they would pursue ART. In contrast, high-income
women were almost two-times as likely to pursue the
ART treatment option (Staniec & Webb, 2007). An
analysis in Germany has shown that introducing IVF/
ICSI co-payments resulted in a shift in utilisation
towards older-aged females which may reflect
increased financial abilities and poorer prognosis
for conception without immediate treatment (DIR,
2005).
The relationship between cost and patient dropout
is better understood because this involves explora-
tion of choices made by couples already being on
treatment. Because treatment costs are high it is
tempting to suggest that this is one of the main
reasons that people do not pursue treatment or
withdraw from treatment once they have initiated.
While cost is often one of the most prominent
variables explaining discontinuation rates, psycholo-
gical factors are often seen to be more influential in
decision making on whether or not to start (Goldfarb
et al., 1997; Malcolm & Cumming, 2004; Rajkhowa
et al., 2006). The limited influence of financial
constraints on dropout rates suggests that cost more
likely influences on whether couples decide to access
treatment at all. This is supported by price-elasticity
studies in other healthcare areas where costs more
often influence decisions to pursue treatment rather
than the volume of consumption once the initial
decision to be treated has been taken (Ringel et al.,
2002). This might suggest that people who can afford
access to ART to begin with are more likely to
discontinue for reasons other than cost.
The externality of fertility treatment outcomes
How much is society willing to pay for an ART-
conceived child? Should fertility treatments be
publicly subsidised? From which perspective do we
evaluate ART-conceived children? These are only
















































some of the questions that economists and policy
analysts are likely to consider regarding fertility
treatments. As the proportion of children born from
ART increases ever year, there is a pressing need to
understand the societal impact of these children who
would not have been born if reproductive technol-
ogies were not available. Furthermore, when the
annual numbers of ART-conceived children are
positioned within the population ageing debate, the
poignancy of this subject takes on heightened
relevance (Hoorens et al., 2007; Sunde, 2007).
Assisted reproductive techniques have been avail-
able for more than 30 years, and to date few studies
have considered the societal implications of the
growing numbers of children that are adding to our
demographic footprint every year. While debate has
focused on ethical issues regarding the delivery of
fertility care, the aggregate number of children born
each year has steadily increased reaching up to 6% of
annual births in some countries (Andersen & Erb
2006). Because of this, ART now attracts the
attention of demographers and economists bringing
with them new approaches for evaluating the impact
of reproductive technology.
The conventional approach for valuing fertility
outcomes is defined in clinical terms based on live
births, adverse events and multiple pregnancies.
What is seldom considered in relation to ART
outcomes is the externality of aggregated fertility
treatment outcomes that goes beyond the benefits
conferred on individual couples. The term ‘extern-
ality’ is used to describe how the actions or inactions
of others can directly or indirectly influence those
unrelated to the initial action. From this perspective,
it is possible to consider how the number of children
born from ART every year can have a measurable
externality that impacts on all of us. Namely that
these children grow to become adults and engage in
economic activities that influence the supply and
demand for goods and eventually pay taxes to
support an increasing proportion of retired persons.
At a time when issues of sustainability are occupying
the minds of many European leaders because of
falling birth rates and ageing populations, it needs to
be recognised that these children make a small but
meaningful contribution to society (Hoorens et al.,
2007; European Parliament, 2008).
In recent years considerable attention has been
given to falling birth rates and ageing populations. In
an economic context these demographic outcomes
can appear rather innocuous. However, in the
knowledge that demographics often drive economies
it is clear that these demographic outcomes do have
economic consequences (Longman, 2004). As such
concerns over birth rates are valid because of their
influence over economies now and in the future, and
in particular the proportion of working aged persons
relative to non-working aged persons that can impact
on public finances. When demographic parameters
are interpreted in an economic context it is clear that
the numbers of children alive now and born in the
future can influence both the absolute number of tax
payers as well as future rates of taxation (Kotlikoff,
1992; Raffelhu¨schen, 1999; Cardarelli et al., 2000;
IGR, 2007). Therefore, birth rates do matter for all
of us.
If babies do matter, then what is the role of ART
and its significance in the ageing debate. Although
the contribution of ART-conceived children to
national birth rates are small, even small changes in
total fertility rates (TFRs) can influence demand for
government services and influence tax revenues over
many generations (Cardarelli et al., 2000). The likely
consequences of demographic changes that are
occurring, and the growing number of ART-con-
ceived children in countries with generous public
subsidy suggest that all of us have an interest,
financial or otherwise, in whether or not reproductive
technology is made available. The same could also be
said for restrictive legislation that inhibits the
effective delivery of fertility treatments (Ciriminna
et al., 2007).
The externality of fertility treatments are exempli-
fied by a 2006 fertility policy decision in Korea. Prior
to 2005, there was no public subsidy of fertility
treatments in Korea. The lack of funding was
reversed in 2006 providing reimbursement for up
to two treatment cycles of IVF per couple. The
funding decision was not an urge of compassion for
infertile couples by the Korean Legislature, rather
the decision was taken because of the baby shortage
that exists in Korea and concerns over future
economic sustainability associated with an ageing
population (Auerbach & Chun, 2003; Kim, 2007).
Korea is not alone in this respect where it has been
argued that Israel’s generous fertility funding is
aligned not only with its pronatalist traditions but
also with achieving demographic goals (Birenbaum-
Carmeli, 2004).
Demographers often study the effectiveness of
population policies used by governments to influence
birth rates in which a TFR of 2.1 is considered
necessary for maintaining a stable population (Grant
et al., 2004). These policies often include subsidised
childcare, baby bonuses and direct financial trans-
fers. The intentions of these policies are varied, often
with the aim of reducing the financial burden of
raising children, but sometimes the aim is more
explicit to increase birth rates. The effectiveness of
such policies is inconclusive, and where effects exist
they are often shown to have limited impact (Grant
et al., 2004). Demographers often conclude that at
best, population policies are more likely to influence
the timing of children rather than the absolute
















































number of children per couple. In contrast, fertility
treatments can directly influence the absolute num-
bers of children born to a particular couple. This is
because non-fecund couples can be made fecund
through medical intervention, thereby contributing
to the TFR.
Demographic exploration of ART policies and live
birth rates has suggested that the contribution of
ART to TFR is comparable to the effects of
population policies used by many governments.
These conclusions were based on examining TFRs
in Denmark and the UK where ART was shown to
account for 0.07 and 0.02 of the TFR in each
country, respectively (Hoorens et al., 2007). When
the contribution of ART was compared with findings
from a review of population policies in OECD
countries, the contribution of ART to TFR was
found to be comparable with population policies
used by governments (Gauthier & Hatzius, 1997;
Hoorens et al., 2007).
The economic value of ART infants
Expenditure on healthcare is increasingly discussed
as an investment that influences economic growth.
In a report to the European Commission, it was
suggested that ‘policy-makers who are interested in
improving economic outcomes (e.g. on the labour
market or for the entire economy) would have
good reasons to consider investment in health as
one of their options by which to meet their
economic objectives (Suhrcke et al., 2005)’. Apply-
ing such a framework to health improvements
highlights that health is a form of human capital
that can be used to produce economic benefits –
namely in the form of labour force participation
and normally valued using labour wage rates (Rice
& Cooper, 1967; Grossman, 1972). The extent to
which this relationship applies to fertility treat-
ments is determined by the known drivers of
economic growth.
To better understand the contribution of fertility
treatments and live births on economic growth it is
useful to consider the model developed by Robert
Solow which defines the determinants of economic
growth. The work conducted by Solow for which
he was later awarded the Nobel Prize in economics
in 1987 describes the three main determinants of
economic growth as: Innovation (A); Capital (K);
and Labour supply (L) (Solow, 1956). According
to the relationship defined in the Solow model an
increase in either A, K or L can lead to economic
growth. Because of this it is possible to position the
future supply of labour (L) attributed to ART-
conceived children within this relationship, and the
economic contribution attributed to the 2–4% of
annual births from ART observed in several
countries. Equally, the relationship helps us to
understand why ageing populations are of concern
because of reductions in the supply of labour that
are imminent in many countries.
Because ART-conceived children represent a pool
of future labour supply, and these children can be
evaluated using human capital ideas, it is possible to
evaluate the benefits of ART in monetary terms
(Rice & Cooper, 1967). In economic terms, invest-
ing healthcare resources to create a life using IVF or
investing to save a life requires the same methodo-
logical framework for valuing human capital.
Whether you save a life or create a life by investing
in health, the end result is the same in that there is
one additional person alive who would not have been
alive if decisive medical care to save or to create life
had not been taken. Accordingly, ART-conceived
children can be valued using human capital methods
using labour market wage rates to assess the value of
a life (Rice & Cooper, 1967).
To give some idea of the benefits to governments
from investing in IVF programs, we previously
explored the return on investment from fertility
programs using a human capital approach and the
resulting tax revenue for government that arise from
investing in ART. The approach applied a narrow
government perspective to calculate lifetime net tax
revenue derived from an IVF-conceived child
(Svensson et al., 2008; Connolly et al., 2009b).
After deducting lifetime direct government financial
transfers such as education, health, allowances and
pensions, the average lifetime net tax contributions
from the government perspective were estimated for
an IVF child. Results from the UK indicate that a
singleton IVF child born in 2005, assuming they are
average in every respect, will pay £110,000 dis-
counted and £603,000 undiscounted lifetime net
taxes (Connolly et al., 2009b). Based on the
investment costs of approximately £13,000 per
IVF-conceived child, this represents more than an
eight-fold return on investment for government in
discounted future tax revenue. This framework is
also useful for highlighting the long timeframes that
are required to evaluate economic benefits from
investing in health programs.
In practice the evidence base suggesting that
population growth stimulates economic prosperity
is unclear (Bloom et al., 2003). Rather, what is
increasingly recognised is that the proportion of
working-aged population relative to economically
inactive cohorts is more likely to influence economic
growth. Therefore, simply increasing birth rates now
whether through natural or assisted conception does
not immediately translate into economic benefits.
Rather, the benefits are observed as these children
enter the workforce – a point supported by the tax-
based evaluation described previously.
















































What is notable with respect to population
policies and the resulting economic benefits are
the long timeframes required for policies to take
effect. Therefore, policies implemented today
require considerable foresight about future age-
dependency ratios and societal needs. This might
suggest that if ART provision were positioned as
pronatalist or population policy, it calls into
question whether health services that often focus
on short time horizons are in a position to
appreciate fully the benefits attributed to ART-
conceived children. Had fertility treatments been
funded by other government departments, for
example, the tax collection agency or family
services, perhaps funding for fertility treatments
would be seen as a much higher priority than often
exists today.
Conclusions
The two economic aspects discussed in this article –
access to fertility treatment and the economic value
of ART-conceived children – although seemingly
distinct, do share some commonality. They are
related by the manner in which health services
perceive expenditure allocated to fertility treat-
ments. In health services where infertility is a low
priority, it attracts limited funding and fertility
treatments are mostly viewed as a cost. Because of
the limited funding, many infertile couples are
unable to access treatment which no doubt
influences the number of children that could be
born every year in the absence of financial barriers.
However, the economic approach applied to value
fertility treatment illustrates that such treatment is
actually an ‘investment’ that yields future economic
benefits. While the benefits are not immediate,
what is viewed as a cost today is actually an
investment, when considered over longer periods of
time.
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